Compare ADMA Biologics Inc (ADMA) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? ADMA Biologics Inc trades at $9.92 (market cap $2.22B), while Norwegian Cruise Line Holdings Ltd trades at $19.04 (market cap $8.59B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 3.9× ADMA Biologics Inc's market cap, and Norwegian Cruise Line Holdings Ltd is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | NCLH | |
|---|---|---|
Market Cap | $2.22B | $8.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $26.94 |
52-Week Low | $7.60 | $14.79 |
Enterprise Value | $2.29B | $23.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
NCLH trades at $18.55, down 3.64% today, amid a bearish technical signal. The company reported Q2 2026 EPS of $0.48, beating estimates, but faces headwinds from high fuel costs and soft demand. Revenue growth is steady, with 2025 revenue at $9.83B, and profitability metrics like a 7.49% net income margin show resilience. Analyst consensus is bullish with a $20.73 price target, though recent news highlights execution risks and macroeconomic pressures.
The outlook is mixed: strong fundamentals and analyst support suggest upside potential, but near-term volatility from cost pressures and travel demand uncertainty poses risks. Investors should weigh the attractive valuation against operational challenges in the cruise industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
